Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
NCT01642407
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Subjects weighing ≥8 kg.
- Subjects who have symptomatic pulmonary arterial hypertension due to one of the following conditions:
- Idiopathic pulmonary arterial hypertension; or
- Heritable pulmonary arterial hypertension; or
- Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts. If the defect(s) is repaired, the subject's condition should be stabilized hemodynamically; or
- Pulmonary arterial hypertension associated with d-transposition of the great arteries repaired within the first 30 days of life; or
- Pulmonary arterial hypertension in subjects who have undergone surgical repair of other congenital heart lesions and the condition should be stabilized hemodynamically and do not have clinically significant residual left-sided heart disease.
- Subjects with a mean pulmonary artery pressure ≥25 mmHg at rest, PCWP ≤15 mmHg, and PVRI ≥3 Wood units x m2. If PCWP is not available, then mean LA pressure ≤15 mmHg or LVEDP ≤15 mmHg in the absence of left atrial obstruction.
- Left-sided heart disease.
- Subjects with Down syndrome.
- Subjects with Obstructive Sleep Apnea, regardless of treatment status.
- Pericardial constriction.
- Subjects with significant (2+ for regurgitation) valvular disease other than tricuspid
or pulmonary regurgitation.
- Acutely decompensated heart failure within previous 30 days from screening.
- Subjects who have had an atrial septostomy within previous 6 months of screening.
- Subjects with hemodynamic instability or hypo- or hypertension at screening.
- Subjects with a history of stroke, myocardial infarction or life threatening
arrhythmia within 6 months of screening.
- Subjects with moderate to severe restrictive pulmonary disease (Total Lung Capacity or
Forced Vital Capacity ≤60% of normal) or history of severe lung disease.
- Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.
- Subjects with history of pulmonary embolism.
- Subjects with known hereditary degenerative retinal disorders (such as retinitis
pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).
- Subjects who are known to be HIV positive.
- Subjects with impairment of renal function (serum creatinine >2.5 × ULN) or hepatic
function (ALT and/or AST >3 × ULN; and/or bilirubin ≥2 mg/dL). Hematological
abnormalities (e.g., severe anemia, Hgb <10 g/dL, leukopenia, WBC <2500/µL).
- Subjects with severe hepatic dysfunction (Child-Pugh classification C).
- Change in class of medication for CHF or PAH within the 10 days prior to qualifying
right heart catheterization.
- Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in
any form.
- Subjects taking chronic arginine supplementation.
- Subjects who have received parenteral inotropic medication or parenteral vasodilators
within 30 days of Day 1.
- Subjects who are receiving alpha-blockers, nicorandil, amiodarone or potent cytochrome
P450 3A4 inhibitors.
- Subjects receiving chronic treatment with off-label sildenafil within 30 days of Day 1
are excluded. Subjects receiving an endothelin antagonist,PED5 inhibitor or,
prostacyclin/prostacyclin analogue within 30 days of randomization are excluded except
for beraprost.
- Pregnant females; breastfeeding females; males and females of childbearing potential
not using highly effective contraception or not agreeing to continue highly effective
contraception for at least 28 days after last dose of investigational product.
- Current or past illicit drug use or alcoholism excepting if abstinence can be
documented for ≥1 year.
- Participation in another clinical trial of an investigational drug or device
(including placebo) within 30 days of screening for entry into the present study.
- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Sagamihara, Kanagawa
- Suita, Osaka
- Ota-ku, Tokyo
- Setagaya-ku, Tokyo
- Shizuoka,
- Fountain Valley, California
- Cluj Napoca,
- Kyiv,
- Fountain Valley, California
- Mather, California
- Sacramento, California
- Englewood, Colorado
- Littleton, Colorado
- Gainesville, Florida
- Sarasota, Florida
- Weston, Florida
- Chicago, Illinois
- Olathe, Kansas
- Towson, Maryland
- Boston, Massachusetts
- Omaha, Nebraska
- New Brunswick, New Jersey
- Islandia, New York
- Stony Brook, New York
- Chapel Hill, North Carolina
- Cincinnati, Ohio
- Cleveland, Ohio
- Lancaster, Pennsylvania
- Lancaster, Pennsylvania
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Providence, Rhode Island
- Charleston, South Carolina
- Dallas, Texas
- Houston, Texas
- San Antonio, Texas
- Temple, Texas
- Lynchburg, Virginia
- Richmond, Virginia
- Milwaukee, Wisconsin
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Sofia,
- Sofia,
- Veliko Turnovo,
- Temuco,
- Changsha, Hunan
- Xi'an, Shanxi
- Beijing,
- Shanghai,
- Shanghai,
- Bogotá, Cundinamarca
- Escazu, San Jose
- Praha 2,
- Santo Domingo, República Dominicana
- Santo Domingo,
- Guatemala,
- Hyderabad, Andhera Pradesh
- Hyderabad, Andhra Pradesh
- Ahmedabad, Gujarat
- Surat, Gujarat
- Vadodara, Gujarat
- Pune, Maharashtra
- Coimbatore, Tamil Nadu
- Madurai, Tamil Nadu
- Georgetown, Penang
- Mexico, DF
- Mexico, DF
- Monterrey, Nuevo Leon
- Lima,
- Lima,
- Quezon City,
- Cluj Napoca,
- Iasi,
- Moscow,
- Moscow,
- Saint-Petersburg,
- Saint-Petersburg,
- Saint-Petersburg,
- Riyadh,
- Belgrade,
- Bratislava,
- Cape Town, Western Cape
- Cape Town,
- Johannesburg,
- Stellenbosch,
- Bangkoknoi, Bangkok
- Bangkok,
- Istanbul, Fatih,
- Kyiv,
- Kyiv,
- Fountain Valley, California
- Gainesville, Florida
- Weston, Florida
- Boston, Massachusetts
- Omaha, Nebraska
- Chapel Hill, North Carolina
- Cincinnati, Ohio
- Cleveland, Ohio
- Providence, Rhode Island
- Houston, Texas
- San Antonio, Texas
- Milwaukee, Wisconsin
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Sofia,
- Temuco,
- Changsha, Hunan
- Beijing,
- Shanghai,
- Shanghai,
- Bogotá, Cundinamarca
- Praha 2,
- Hyderabad, Andhra Pradesh
- Hyderabad, Andhra Pradesh
- Ahmedabad, Gujarat
- Ahmedabad, Gujarat
- Surat, Gujarat
- Vadodara, Gujarat
- Pune, Maharashtra
- Coimbatore, Tamil Nadu
- Madurai, Tamil Nadu
- Georgetown, Penang
- Monterrey, Nuevo Leon
- Lima,
- Cluj Napoca,
- Iasi,
- Moscow,
- Moscow,
- Saint-Petersburg,
- Saint-Petersburg,
- Belgrade,
- Johannesburg,
- Bangkoknoi, Bangkok
- Istanbul, Fatih,
- Kyiv,
- Kyiv,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension | |||
Official Title ICMJE | A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension | |||
Brief Summary | Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. In many patients, the course of PAH is a steady deterioration and reduced life expectancy. Sildenafil was approved by the European Commission for the treatment of PAH in pediatric patients in May 2011, making it the first agent to be approved for the treatment of children with PAH. The approval was based on the largest placebo-controlled study to be conducted in this population. The recommended dose in pediatric patients aged 1 year to 17 years old is 10 mg TID in patients ? 20 kg and 20 mg TID for patients > 20 kg. Higher doses are not recommended in pediatrics patients. This study is an open-label, multi-center study to investigate safety, efficacy and pharmacokinetics of sildenafil citrate in Japanese pediatric patients with PAH. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE | Drug: Sildenafil
Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ? 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2 | |||
Study Arms ICMJE | Experimental: Sildenafil
Intervention: Drug: Sildenafil | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 6 | |||
Original Estimated Enrollment ICMJE | 10 | |||
Actual Study Completion Date ICMJE | March 12, 2018 | |||
Actual Primary Completion Date | May 20, 2016 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 1 Year to 17 Years (Child) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Japan | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT01642407 | |||
Other Study ID Numbers ICMJE | A1481298 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |